Zealand Pharma A/S (CPH: ZEAL)

Market Cap	62.88B
Revenue (ttm)	367.97M
Net Income (ttm)	-712.00M
Shares Out	70.94M
EPS (ttm)	-11.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,155,592
Open	871.50
Previous Close	871.50
Day's Range	871.50 - 901.50
52-Week Range	252.60 - 972.00
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 253
• Stock Exchange: Nasdaq Copenhagen
• Ticker Symbol: ZEAL

Financial Performance

In 2023, Zealand Pharma's revenue was 342.79 million, an increase of 229.65% compared to the previous year's 103.99 million. Losses were -703.74 million, -41.46% less than in 2022.